Protalix CFO updates Form 3 share and option holdings
Protalix BioTherapeutics, Inc. senior vice president and CFO Gilad Mamlok reports his equity holdings in an amended Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3/A
Rhea-AI Filing Summary
Protalix BioTherapeutics, Inc. senior vice president and CFO Gilad Mamlok reports his equity holdings in an amended Form 3. He holds 3,631 shares of common stock directly. He also holds stock options covering 597,990 shares of common stock at an exercise price of $1.45 per share, expiring on July 20, 2035. These options vest in 12 equal quarterly installments from the grant date and can vest faster if there is a corporate transaction or change in control under the company’s Amended and Restated 2006 Stock Incentive Plan.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Mamlok Gilad
Role
Sr. VP and CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 597,990 contracts (Direct);
Common Stock — 3,631 shares (Direct)
Footnotes (1)
- F1. The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended.
Key Figures
Direct common shares: 3,631 shares
Underlying option shares: 597,990 shares
Option exercise price: $1.45 per share
+3 more
6 metrics
Direct common shares
3,631 shares
Total shares of common stock held directly after reported holdings
Underlying option shares
597,990 shares
Common shares underlying reported stock options held by CFO
Option exercise price
$1.45 per share
Exercise price of stock options on 597,990 underlying shares
Option expiration
July 20, 2035
Expiration date of the reported stock options
Vesting installments
12 quarterly installments
Options vest in 12 equal quarterly installments from grant date
Unknown transaction entries
2 entries
Filing shows two holding entries with unknown transaction codes
Key Terms
Stock Option (Right to Buy), change in control, Amended and Restated 2006 Stock Incentive Plan, vesting
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with underlying common stock"
change in control financial
"subject to accelerated vesting upon a corporate transaction or a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Amended and Restated 2006 Stock Incentive Plan financial
"as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended"
vesting financial
"shares of common stock underlying the stock options shall vest in 12 equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Protalix BioTherapeutics (PLX) CFO Gilad Mamlok report in this amended Form 3?
He reports his current equity holdings in Protalix BioTherapeutics. This includes directly held common shares and a large stock option position that can convert into common stock under specified terms and vesting conditions detailed in the company’s stock incentive plan.
What stock options in Protalix BioTherapeutics (PLX) does the CFO report holding?
He reports stock options labeled as a “Stock Option (Right to Buy)” tied to 597,990 underlying common shares. These options give him the right to purchase Protalix common stock at a fixed exercise price, subject to vesting over time and the stated expiration date.
What is the exercise price and expiration date of the CFO’s Protalix (PLX) stock options?
The stock options have an exercise price of $1.45 per share and expire on July 20, 2035. This means he can buy up to 597,990 shares at $1.45 each before that expiration date, assuming the options vest and remain outstanding.
How do the Protalix (PLX) CFO’s stock options vest according to the filing?
The options vest in 12 equal quarterly installments starting on the grant date. This schedule gradually makes portions of the 597,990-share option exercisable, aligning the CFO’s long-term incentives with the company’s ongoing performance over multiple quarters.
What happens to the Protalix (PLX) CFO’s options if there is a change in control?
The filing states the options are subject to accelerated vesting upon a corporate transaction or change in control. Under the company’s Amended and Restated 2006 Stock Incentive Plan, such an event can cause unvested portions of the options to vest more quickly than the standard quarterly schedule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates